Lipid-Based Nanomedicine for Alzheimer's Disease: A Comprehensive Review of Recent Advances.

Q2 Pharmacology, Toxicology and Pharmaceutics

Pharmaceutical nanotechnology Pub Date : 2024-06-11 DOI:10.2174/0122117385300234240522100826

Sanchit Dhankhar, Nitika Garg, Himanshu Sharma, Samrat Chauhan, Monika Saini

{"title":"Lipid-Based Nanomedicine for Alzheimer's Disease: A Comprehensive Review of Recent Advances.","authors":"Sanchit Dhankhar, Nitika Garg, Himanshu Sharma, Samrat Chauhan, Monika Saini","doi":"10.2174/0122117385300234240522100826","DOIUrl":null,"url":null,"abstract":"Background: Alzheimer's disease (AD) is the most common form of dementia and is expected to greatly rise in future, making it a major worldwide health concern with severe impacts on individuals and society. Despite advancements in understanding the cellular and molecular aspects of Alzheimer's disease (AD) in recent decades, it still poses a significant problem. A major problem is accurately delivering drugs to diseased neurons while minimising effects on healthy neurons. This difficulty is worsened by the low water solubility of anti-Alzheimer's disease medicines and the blood-brain barrier (BBB) that hinders the entry of central nervous system pharmaceuticals that are highly lipophilic.Objective: The focus of this article is on nanocarriers that are lipid-based. This is one of the more widely accepted methods of treating Alzheimer's disease, as it increases therapeutic efficacy while decreasing side effects related to cooperated neurological disorder payload.Method: Searched many databases for papers published under the title (including PubMed, Elsevier, and Google Scholar).Results/conclusion: Nano Lipid Carriers (NLCs) are recognized for their ability to target the brain effectively due to their lipid-loving properties and compatibility with living tissues. They improve the absorption of drugs in the brain while decreasing the accumulation of drugs in unintended organs. This work emphasises the importance of nano lipid carriers, which are lipophilic and biocompatible and have demonstrated exceptional targeting efficiency, making them an ideal carrier system for delivering medications to the brain.","PeriodicalId":19774,"journal":{"name":"Pharmaceutical nanotechnology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical nanotechnology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0122117385300234240522100826","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Alzheimer's disease (AD) is the most common form of dementia and is expected to greatly rise in future, making it a major worldwide health concern with severe impacts on individuals and society. Despite advancements in understanding the cellular and molecular aspects of Alzheimer's disease (AD) in recent decades, it still poses a significant problem. A major problem is accurately delivering drugs to diseased neurons while minimising effects on healthy neurons. This difficulty is worsened by the low water solubility of anti-Alzheimer's disease medicines and the blood-brain barrier (BBB) that hinders the entry of central nervous system pharmaceuticals that are highly lipophilic.

Objective: The focus of this article is on nanocarriers that are lipid-based. This is one of the more widely accepted methods of treating Alzheimer's disease, as it increases therapeutic efficacy while decreasing side effects related to cooperated neurological disorder payload.

Method: Searched many databases for papers published under the title (including PubMed, Elsevier, and Google Scholar).

Results/conclusion: Nano Lipid Carriers (NLCs) are recognized for their ability to target the brain effectively due to their lipid-loving properties and compatibility with living tissues. They improve the absorption of drugs in the brain while decreasing the accumulation of drugs in unintended organs. This work emphasises the importance of nano lipid carriers, which are lipophilic and biocompatible and have demonstrated exceptional targeting efficiency, making them an ideal carrier system for delivering medications to the brain.

查看原文本刊更多论文

基于脂质的纳米药物治疗阿尔茨海默病：最新进展综述》。

背景：阿尔茨海默病（AD）是最常见的痴呆症，预计今后将大幅增加，成为全球关注的主要健康问题，对个人和社会造成严重影响。尽管近几十年来人们对阿尔茨海默病（AD）的细胞和分子方面的认识取得了进步，但它仍然是一个重大问题。一个主要问题是如何准确地将药物输送到患病神经元，同时尽量减少对健康神经元的影响。由于抗阿尔茨海默病药物的水溶性较低，而血脑屏障（BBB）又阻碍了亲脂性较强的中枢神经系统药物的进入，因此这一难题更加严峻：本文的重点是基于脂质的纳米载体。这是目前较为广泛接受的治疗阿尔茨海默病的方法之一，因为它在提高疗效的同时减少了与配合神经紊乱有效载荷有关的副作用：搜索了许多数据库中以该标题发表的论文（包括 PubMed、Elsevier 和 Google Scholar）：纳米脂质载体（NLCs）因其亲脂特性和与活体组织的相容性而被公认为能够有效靶向大脑。纳米脂质载体可促进药物在大脑中的吸收，同时减少药物在非预期器官中的蓄积。这项工作强调了纳米脂质载体的重要性，因为纳米脂质载体具有亲脂性和生物相容性，并已证明具有卓越的靶向效率，使其成为向大脑输送药物的理想载体系统。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmaceutical nanotechnology Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science

CiteScore

4.20

自引率

0.00%

发文量

期刊介绍： Pharmaceutical Nanotechnology publishes original manuscripts, full-length/mini reviews, thematic issues, rapid technical notes and commentaries that provide insights into the synthesis, characterisation and pharmaceutical (or diagnostic) application of materials at the nanoscale. The nanoscale is defined as a size range of below 1 µm. Scientific findings related to micro and macro systems with functionality residing within features defined at the nanoscale are also within the scope of the journal. Manuscripts detailing the synthesis, exhaustive characterisation, biological evaluation, clinical testing and/ or toxicological assessment of nanomaterials are of particular interest to the journal’s readership. Articles should be self contained, centred around a well founded hypothesis and should aim to showcase the pharmaceutical/ diagnostic implications of the nanotechnology approach. Manuscripts should aim, wherever possible, to demonstrate the in vivo impact of any nanotechnological intervention. As reducing a material to the nanoscale is capable of fundamentally altering the material’s properties, the journal’s readership is particularly interested in new characterisation techniques and the advanced properties that originate from this size reduction. Both bottom up and top down approaches to the realisation of nanomaterials lie within the scope of the journal.